

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	NeuroScientific Biopharmaceuticals Limited
ABN	13 102 832 995

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Anton Uvarov
Date of last notice	7 / 12 /2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Yulia Uvarova (wife) <Techinvest Nominees>
Date of change	27 July 2020

Appendix 3Y

Change of Director's Interest Notice

No. of securities held prior to change	<p><u>Direct:</u></p> <p>350,000 Ordinary shares (Escrowed until 27 July 2020)</p> <p>150,000 Class B Performance Shares (Escrowed until 27 July 2020)</p> <p>150,000 Class C Performance Shares (Escrowed until 27 July 2020)</p> <p>150,000 Class D Performance Shares (Escrowed until 27 July 2020)</p> <p>150,000 Class E Performance Shares (Escrowed until 27 July 2020)</p> <p>140,000 Unlisted Options (exercisable at \$0.20 on or before 7 March 2021)</p> <p>700,000 Unlisted Options (exercisable at \$0.30 on or before 17 December 2022)</p> <p><u>Indirect:</u></p> <p>1,275,000 Ordinary shares (1,075,000 escrowed until 27 July 2020)</p> <p>510,000 Unlisted Options (exercisable at \$0.20 on or before 7 March 2021)</p>
Class	Ordinary Shares, unlisted options and performance
Number acquired	<p>Direct : 350,000 ordinary shares, 600,000 performance shares out of escrow</p> <p>Indirect: 1,075,000 ordinary shares, 510,000 options out of escrow</p>
Number disposed	<p>Direct: n/a</p> <p>Indirect: n/a</p>
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<p>Direct: \$nil</p> <p>Indirect: \$nil</p>

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	<p>Direct:</p> <p>350,000 Ordinary shares</p> <p>150,000 Class B Performance Shares</p> <p>150,000 Class C Performance Shares</p> <p>150,000 Class D Performance Shares</p> <p>150,000 Class E Performance Shares</p> <p>140,000 Unlisted Options (exercisable at \$0.20 on or before 7 March 2021)</p> <p>700,000 Unlisted Options (exercisable at \$0.30 on or before 17 December 2022)</p> <p>Indirect:</p> <p>1,275,000 Ordinary shares</p> <p>510,000 Unlisted Options (exercisable at \$0.20 on or before 7 March 2021)</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Escrow period expired across various holdings

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder (if issued securities)	-
Date of change	-
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	-
Interest acquired	-

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Interest disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	-
Interest after change	-

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.